Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells

DOI record: { "DOI": "10.1038/s41598-022-19993-w", "ISSN": [ "2045-2322" ], "URL": "http://dx.doi.org/10.1038/s41598-022-19993-w", "abstract": "<jats:title>Abstract</jats:title><jats:p>Many therapeutic antibodies (Abs) and mRNA vaccines, both targeting SARS-CoV-2 spike protein (S-protein), have been developed and approved in order to combat the ongoing COVID-19 pandemic. In consideration of these developments, a common concern has been the potential for Ab-dependent enhancement (ADE) of infection caused by inoculated or induced Abs. Although the preventive and therapeutic effects of these Abs are obvious, little attention has been paid to the influence of the remaining and dwindling anti-S-protein Abs in vivo. Here, we demonstrate that certain monoclonal Abs (mAbs) approved as therapeutic neutralizing anti-S-protein mAbs for human usage have the potential to cause ADE in a narrow range of Ab concentrations. Although sera collected from mRNA-vaccinated individuals exhibited neutralizing activity, some sera gradually exhibited dominance of ADE activity in a time-dependent manner. None of the sera examined exhibited neutralizing activity against infection with the Omicron strain. Rather, some ADE of Omicron infection was observed in some sera. These results suggest the possible emergence of adverse effects caused by these Abs in addition to the therapeutic or preventive effect.</jats:p>", "alternative-id": [ "19993" ], "article-number": "15612", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "3 May 2022" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "7 September 2022" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "16 September 2022" }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 1, "value": "The authors declare no competing interests." } ], "author": [ { "affiliation": [], "family": "Shimizu", "given": "Jun", "sequence": "first" }, { "affiliation": [], "family": "Sasaki", "given": "Tadahiro", "sequence": "additional" }, { "affiliation": [], "family": "Koketsu", "given": "Ritsuko", "sequence": "additional" }, { "affiliation": [], "family": "Morita", "given": "Ryo", "sequence": "additional" }, { "affiliation": [], "family": "Yoshimura", "given": "Yuka", "sequence": "additional" }, { "affiliation": [], "family": "Murakami", "given": "Ami", "sequence": "additional" }, { "affiliation": [], "family": "Saito", "given": "Yua", "sequence": "additional" }, { "affiliation": [], "family": "Kusunoki", "given": "Toshie", "sequence": "additional" }, { "affiliation": [], "family": "Samune", "given": "Yoshihiro", "sequence": "additional" }, { "affiliation": [], "family": "Nakayama", "given": "Emi E.", "sequence": "additional" }, { "affiliation": [], "family": "Miyazaki", "given": "Kazuo", "sequence": "additional" }, { "affiliation": [], "family": "Shioda", "given": "Tatsuo", "sequence": "additional" } ], "container-title": "Scientific Reports", "container-title-short": "Sci Rep", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2022, 9, 16 ] ], "date-time": "2022-09-16T16:04:09Z", "timestamp": 1663344249000 }, "deposited": { "date-parts": [ [ 2022, 9, 16 ] ], "date-time": "2022-09-16T16:17:13Z", "timestamp": 1663345033000 }, "funder": [ { "DOI": "10.13039/100009619", "award": [ "JP20he0822004" ], "doi-asserted-by": "crossref", "name": "the Japan Agency for Medical Research and Development" } ], "indexed": { "date-parts": [ [ 2022, 12, 27 ] ], "date-time": "2022-12-27T12:53:44Z", "timestamp": 1672145624652 }, "is-referenced-by-count": 2, "issue": "1", "issued": { "date-parts": [ [ 2022, 9, 16 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2022, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 9, 16 ] ], "date-time": "2022-09-16T00:00:00Z", "timestamp": 1663286400000 } }, { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 9, 16 ] ], "date-time": "2022-09-16T00:00:00Z", "timestamp": 1663286400000 } } ], "link": [ { "URL": "https://www.nature.com/articles/s41598-022-19993-w.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-022-19993-w", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-022-19993-w.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1038", "published": { "date-parts": [ [ 2022, 9, 16 ] ] }, "published-online": { "date-parts": [ [ 2022, 9, 16 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1126/science.abd0827", "author": "J Hansen", "doi-asserted-by": "publisher", "first-page": "1010", "journal-title": "Science", "key": "19993_CR1", "unstructured": "Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010–1014 (2020).", "volume": "369", "year": "2020" }, { "DOI": "10.1056/NEJMoa2035002", "author": "DM Weinreich", "doi-asserted-by": "publisher", "first-page": "238", "journal-title": "N. Engl. J. Med.", "key": "19993_CR2", "unstructured": "Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N. Engl. J. Med. 384, 238–251 (2021).", "volume": "384", "year": "2021" }, { "DOI": "10.1007/s40265-021-01620-z", "author": "ED Deeks", "doi-asserted-by": "publisher", "first-page": "2047", "journal-title": "Drugs", "key": "19993_CR3", "unstructured": "Deeks, E. D. Casirivimab/Imdevimab: First approval. Drugs 81, 2047–2055 (2021).", "volume": "81", "year": "2021" }, { "DOI": "10.1056/NEJMra2035343", "author": "MC Castells", "doi-asserted-by": "publisher", "first-page": "643", "journal-title": "N. Engl. J. Med.", "key": "19993_CR4", "unstructured": "Castells, M. C. & Phillips, E. J. Maintaining safety with SARS-CoV-2 vaccines. N. Engl. J. Med. 384, 643–649 (2021).", "volume": "384", "year": "2021" }, { "DOI": "10.1056/NEJMoa2101544", "author": "J Sadoff", "doi-asserted-by": "publisher", "first-page": "2187", "journal-title": "N. Engl. J. Med.", "key": "19993_CR5", "unstructured": "Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med. 384, 2187–2201 (2021).", "volume": "384", "year": "2021" }, { "DOI": "10.1056/NEJMoa2035389", "author": "LR Baden", "doi-asserted-by": "publisher", "first-page": "403", "journal-title": "N. Engl. J. Med.", "key": "19993_CR6", "unstructured": "Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).", "volume": "384", "year": "2021" }, { "DOI": "10.1016/S0140-6736(21)00234-8", "author": "DY Logunov", "doi-asserted-by": "publisher", "first-page": "671", "journal-title": "The Lancet", "key": "19993_CR7", "unstructured": "Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet 397, 671–681 (2021).", "volume": "397", "year": "2021" }, { "DOI": "10.1038/s41541-016-0003-3", "author": "M Xu", "doi-asserted-by": "publisher", "first-page": "2", "journal-title": "NPJ Vaccines", "key": "19993_CR8", "unstructured": "Xu, M. et al. A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus. NPJ Vaccines 2, 2 (2017).", "volume": "2", "year": "2017" }, { "DOI": "10.1016/j.vaccine.2008.10.087", "author": "W Huisman", "doi-asserted-by": "publisher", "first-page": "505", "journal-title": "Vaccine", "key": "19993_CR9", "unstructured": "Huisman, W., Martina, B. E., Rimmelzwaan, G. F., Gruters, R. A. & Osterhaus, A. D. Vaccine-induced enhancement of viral infections. Vaccine 27, 505–512 (2009).", "volume": "27", "year": "2009" }, { "DOI": "10.1056/NEJMoa1506223", "author": "SR Hadinegoro", "doi-asserted-by": "publisher", "first-page": "1195", "journal-title": "N. Engl. J. Med.", "key": "19993_CR10", "unstructured": "Hadinegoro, S. R. et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373, 1195–1206 (2015).", "volume": "373", "year": "2015" }, { "DOI": "10.1038/s41564-020-00789-5", "author": "WS Lee", "doi-asserted-by": "publisher", "first-page": "1185", "journal-title": "Nat. Microbiol.", "key": "19993_CR11", "unstructured": "Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat. Microbiol. 5, 1185–1191 (2020).", "volume": "5", "year": "2020" }, { "DOI": "10.1016/j.cell.2021.06.021", "author": "D Li", "doi-asserted-by": "publisher", "first-page": "4203", "journal-title": "Cell", "key": "19993_CR12", "unstructured": "Li, D. et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell 184, 4203–4219 (2021).", "volume": "184", "year": "2021" }, { "DOI": "10.1038/s41467-020-19568-1", "author": "S Wang", "doi-asserted-by": "publisher", "first-page": "5752", "journal-title": "Nat. Commun.", "key": "19993_CR13", "unstructured": "Wang, S. et al. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat. Commun. 11, 5752 (2020).", "volume": "11", "year": "2020" }, { "DOI": "10.1016/j.celrep.2021.108699", "author": "Y Zhou", "doi-asserted-by": "publisher", "journal-title": "Cell Rep.", "key": "19993_CR14", "unstructured": "Zhou, Y. et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 34, 108699 (2021).", "volume": "34", "year": "2021" }, { "DOI": "10.1007/s00408-020-00408-4", "author": "F Scialo", "doi-asserted-by": "publisher", "first-page": "867", "journal-title": "Lung", "key": "19993_CR15", "unstructured": "Scialo, F. et al. ACE2: The major cell entry receptor for SARS-CoV-2. Lung 198, 867–877 (2020).", "volume": "198", "year": "2020" }, { "DOI": "10.1016/j.cell.2020.02.058", "author": "AC Walls", "doi-asserted-by": "publisher", "first-page": "281", "journal-title": "Cell", "key": "19993_CR16", "unstructured": "Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292 (2020).", "volume": "181", "year": "2020" }, { "DOI": "10.1016/j.cell.2020.04.004", "author": "V Monteil", "doi-asserted-by": "publisher", "first-page": "905", "journal-title": "Cell", "key": "19993_CR17", "unstructured": "Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181, 905–913 (2020).", "volume": "181", "year": "2020" }, { "DOI": "10.1038/s41467-020-20602-5", "author": "C Kim", "doi-asserted-by": "publisher", "first-page": "288", "journal-title": "Nat. Commun.", "key": "19993_CR18", "unstructured": "Kim, C. et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat. Commun. 12, 288 (2021).", "volume": "12", "year": "2021" }, { "DOI": "10.1038/s41598-021-91746-7", "author": "D Mannar", "doi-asserted-by": "publisher", "first-page": "12448", "journal-title": "Sci. Rep.", "key": "19993_CR19", "unstructured": "Mannar, D., Leopold, K. & Subramaniam, S. Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry. Sci. Rep. 11, 12448 (2021).", "volume": "11", "year": "2021" }, { "DOI": "10.1016/j.cell.2021.06.002", "author": "R Copin", "doi-asserted-by": "publisher", "first-page": "3949", "journal-title": "Cell", "key": "19993_CR20", "unstructured": "Copin, R. et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell 184, 3949–3961 (2021).", "volume": "184", "year": "2021" }, { "DOI": "10.1126/science.abd0831", "author": "A Baum", "doi-asserted-by": "publisher", "first-page": "1014", "journal-title": "Science", "key": "19993_CR21", "unstructured": "Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014–1018 (2020).", "volume": "369", "year": "2020" }, { "key": "19993_CR22", "unstructured": "Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Regen-Cov (Casirivimab and Imdevimab) https://www.fda.gov/media/145611/download.) (2021)." }, { "DOI": "10.1128/mBio.01987-21", "author": "T Maemura", "doi-asserted-by": "publisher", "first-page": "e0198721", "journal-title": "mBio", "key": "19993_CR23", "unstructured": "Maemura, T. et al. Antibody-dependent enhancement of SARS-CoV-2 infection is mediated By the IgG receptors FcgammaRIIA and FcgammaRIIIA but does not contribute to aberrant cytokine production by macrophages. mBio 12, e0198721 (2021).", "volume": "12", "year": "2021" }, { "DOI": "10.1016/j.isci.2021.103720", "author": "Z Wang", "doi-asserted-by": "publisher", "first-page": "103720", "journal-title": "iScience", "key": "19993_CR24", "unstructured": "Wang, Z. et al. ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 infection. iScience 25, 103720 (2022).", "volume": "25", "year": "2022" }, { "DOI": "10.1038/s41598-021-03273-0", "author": "J Shimizu", "doi-asserted-by": "publisher", "first-page": "23713", "journal-title": "Sci. Rep.", "key": "19993_CR25", "unstructured": "Shimizu, J. et al. The potential of COVID-19 patients’ sera to cause antibody-dependent enhancement of infection and IL-6 production. Sci. Rep. 11, 23713 (2021).", "volume": "11", "year": "2021" }, { "author": "AL Cathcart", "first-page": "1123", "journal-title": "bioRxiv", "key": "19993_CR26", "unstructured": "Cathcart, A. L. et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv 35, 1123 (2021).", "volume": "35", "year": "2021" }, { "DOI": "10.1056/NEJMoa2107934", "author": "A Gupta", "doi-asserted-by": "publisher", "first-page": "1941", "journal-title": "N. Engl. J. Med.", "key": "19993_CR27", "unstructured": "Gupta, A. et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941–1950 (2021).", "volume": "385", "year": "2021" }, { "DOI": "10.1038/s41586-022-04411-y", "author": "R Viana", "doi-asserted-by": "publisher", "first-page": "679", "journal-title": "Nature", "key": "19993_CR28", "unstructured": "Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679–686 (2022).", "volume": "603", "year": "2022" }, { "DOI": "10.1056/NEJMc2119407", "author": "E Takashita", "doi-asserted-by": "publisher", "first-page": "995", "journal-title": "N. Engl. J. Med.", "key": "19993_CR29", "unstructured": "Takashita, E. et al. Efficacy of antibodies and antiviral drugs against covid-19 omicron variant. N. Engl. J. Med. 386, 995–998 (2022).", "volume": "386", "year": "2022" }, { "DOI": "10.1016/j.cell.2021.05.032", "author": "Y Liu", "doi-asserted-by": "publisher", "first-page": "3452", "journal-title": "Cell", "key": "19993_CR30", "unstructured": "Liu, Y. et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell 184, 3452–3466 (2021).", "volume": "184", "year": "2021" }, { "DOI": "10.1056/NEJMc2103916", "author": "N Doria-Rose", "doi-asserted-by": "publisher", "first-page": "2259", "journal-title": "N. Engl. J. Med.", "key": "19993_CR31", "unstructured": "Doria-Rose, N. et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N. Engl. J. Med. 384, 2259–2261 (2021).", "volume": "384", "year": "2021" }, { "key": "19993_CR32", "unstructured": "Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity (https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-immunity.html).) (2021)." }, { "DOI": "10.15212/ZOONOSES-2021-0024", "author": "S Qin", "doi-asserted-by": "publisher", "journal-title": "Zoonoses", "key": "19993_CR33", "unstructured": "Qin, S. et al. Genome characterization and potential risk assessment of the novel SARS-CoV-2 variant omicron (B.1.1.529). Zoonoses https://doi.org/10.15212/ZOONOSES-2021-0024 (2021).", "year": "2021" }, { "DOI": "10.1038/s41586-021-04387-1", "author": "S Cele", "doi-asserted-by": "publisher", "first-page": "654", "journal-title": "Nature", "key": "19993_CR34", "unstructured": "Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654–656 (2021).", "volume": "602", "year": "2021" }, { "DOI": "10.1038/s41586-022-04474-x", "author": "B Meng", "doi-asserted-by": "publisher", "first-page": "706", "journal-title": "Nature", "key": "19993_CR35", "unstructured": "Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature 603, 706–714 (2022).", "volume": "603", "year": "2022" }, { "DOI": "10.1038/s41467-022-28544-w", "author": "J Zou", "doi-asserted-by": "publisher", "first-page": "852", "journal-title": "Nat. Commun.", "key": "19993_CR36", "unstructured": "Zou, J. et al. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. Nat. Commun. 13, 852 (2022).", "volume": "13", "year": "2022" }, { "DOI": "10.1172/jci.insight.92428", "author": "YW Kam", "doi-asserted-by": "publisher", "journal-title": "JCI Insight", "key": "19993_CR37", "unstructured": "Kam, Y. W. et al. Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections. JCI Insight 2, e92428 (2017).", "volume": "2", "year": "2017" }, { "DOI": "10.1016/j.humimm.2013.05.017", "author": "M Haruta", "doi-asserted-by": "publisher", "first-page": "1400", "journal-title": "Hum. Immunol.", "key": "19993_CR38", "unstructured": "Haruta, M. et al. Generation of a large number of functional dendritic cells from human monocytes expanded by forced expression of cMYC plus BMI1. Hum. Immunol. 74, 1400–1408 (2013).", "volume": "74", "year": "2013" }, { "DOI": "10.1038/gt.2012.59", "author": "M Haruta", "doi-asserted-by": "publisher", "first-page": "504", "journal-title": "Gene Ther.", "key": "19993_CR39", "unstructured": "Haruta, M. et al. TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells. Gene Ther. 20, 504–513 (2013).", "volume": "20", "year": "2013" } ], "reference-count": 39, "references-count": 39, "relation": {}, "resource": { "primary": { "URL": "https://www.nature.com/articles/s41598-022-19993-w" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Multidisciplinary" ], "subtitle": [], "title": "Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "12" }